NO20004363D0 - Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism - Google Patents

Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism

Info

Publication number: NO20004363D0
Authority: NO; Norway
Prior art keywords: disorders; autism; obsessive; antagonists; treatment
Prior art date: 1998-03-02

Application number

NO20004363A

Other languages

Norwegian (no)

Other versions

NO20004363L (en

Inventor

Vicki L Coffin

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-02

Filing date

2000-09-01

Publication date

2000-09-01

2000-09-01 Application filed by Schering Corp filed Critical Schering Corp

2000-09-01 Publication of NO20004363D0 publication Critical patent/NO20004363D0/en

2000-10-31 Publication of NO20004363L publication Critical patent/NO20004363L/en

Links

206010003805 Autism Diseases 0.000 title 1
208000020706 Autistic disease Diseases 0.000 title 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 title 1
208000030990 Impulse-control disease Diseases 0.000 title 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 title 1
208000027520 Somatoform disease Diseases 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
208000018459 dissociative disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

NO20004363A 1998-03-02 2000-09-01 Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism NO20004363L (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3320598A	1998-03-02	1998-03-02
PCT/US1999/003721 WO1999044615A1 (en)	1998-03-02	1999-03-01	Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism

Publications (2)

Publication Number	Publication Date
NO20004363D0 true NO20004363D0 (en)	2000-09-01
NO20004363L NO20004363L (en)	2000-10-31

Family

ID=21869083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004363A NO20004363L (en)	1998-03-02	2000-09-01	Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism

Country Status (16)

Country	Link
EP (1)	EP1058551A1 (en)
JP (1)	JP2002505291A (en)
KR (1)	KR20010041477A (en)
CN (1)	CN1291893A (en)
AR (1)	AR018297A1 (en)
AU (1)	AU2778099A (en)
BR (1)	BR9908392A (en)
CA (1)	CA2322201A1 (en)
CO (1)	CO4910136A1 (en)
HU (1)	HUP0101057A3 (en)
IL (1)	IL137715A0 (en)
NO (1)	NO20004363L (en)
PE (1)	PE20000333A1 (en)
SK (1)	SK12962000A3 (en)
WO (1)	WO1999044615A1 (en)
ZA (1)	ZA991638B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6410527B1 (en) *	1998-03-02	2002-06-25	Schering Corporation	Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
RU2374245C1 (en)	2008-08-22	2009-11-27	Андрей Александрович Иващенко	Ligand with wide range of simultaneous receptor activity, pharmaceutical composition, method of preparing said composition and medicinal agent
EP4616915A3 (en) *	2012-07-12	2025-12-17	Emalex Biosciences, Inc.	Ecopipam for treatment of tourettes syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5605897A (en) *	1991-04-23	1997-02-25	Eli Lilly And Company	2-methyl-thieno-benzodiazepine
IL135659A0 (en) *	1997-10-28	2001-05-20	Schering Corp	Method of reducing craving in mammals

1999
- 1999-03-01 CO CO99012525A patent/CO4910136A1/en unknown
- 1999-03-01 JP JP2000534217A patent/JP2002505291A/en not_active Withdrawn
- 1999-03-01 AR ARP990100860A patent/AR018297A1/en unknown
- 1999-03-01 SK SK1296-2000A patent/SK12962000A3/en unknown
- 1999-03-01 EP EP99908318A patent/EP1058551A1/en not_active Withdrawn
- 1999-03-01 IL IL13771599A patent/IL137715A0/en unknown
- 1999-03-01 BR BR9908392-2A patent/BR9908392A/en not_active IP Right Cessation
- 1999-03-01 HU HU0101057A patent/HUP0101057A3/en unknown
- 1999-03-01 CN CN99803496A patent/CN1291893A/en active Pending
- 1999-03-01 ZA ZA9901638A patent/ZA991638B/en unknown
- 1999-03-01 WO PCT/US1999/003721 patent/WO1999044615A1/en not_active Ceased
- 1999-03-01 KR KR1020007009634A patent/KR20010041477A/en not_active Withdrawn
- 1999-03-01 CA CA002322201A patent/CA2322201A1/en not_active Abandoned
- 1999-03-01 AU AU27780/99A patent/AU2778099A/en not_active Abandoned
- 1999-03-01 PE PE1999000169A patent/PE20000333A1/en not_active Application Discontinuation
2000
- 2000-09-01 NO NO20004363A patent/NO20004363L/en unknown

Also Published As

Publication number	Publication date
CA2322201A1 (en)	1999-09-10
HUP0101057A3 (en)	2001-09-28
WO1999044615A1 (en)	1999-09-10
AU2778099A (en)	1999-09-20
HUP0101057A2 (en)	2001-08-28
AR018297A1 (en)	2001-11-14
NO20004363L (en)	2000-10-31
ZA991638B (en)	1999-09-01
SK12962000A3 (en)	2001-08-06
PE20000333A1 (en)	2000-05-13
BR9908392A (en)	2000-10-31
CN1291893A (en)	2001-04-18
JP2002505291A (en)	2002-02-19
KR20010041477A (en)	2001-05-25
IL137715A0 (en)	2001-10-31
CO4910136A1 (en)	2000-04-24
EP1058551A1 (en)	2000-12-13

Similar Documents

Publication	Publication Date	Title
MXPA03007960A (en)	2003-12-04	Compounds and methods for the treatment of urogenital disorders.
PL370163A1 (en)	2005-05-16	Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
DK1459750T3 (en)	2005-08-15	(S, S) rebexetine for the treatment of fibromyalgia and other somatoform disorders
PT2266594E (en)	2015-08-05	Vegf for use in the treatment of central nervous system disorders
DK1047428T3 (en)	2007-10-08	Use of morpholinol in the treatment of sexual disorders
IS5113A (en)	1999-07-12	Use of CB1 antagonists for the treatment of craving disorders
NO20043085L (en)	2004-07-13	Methods and compositions for the treatment of central nervous system disorders
DK1063990T3 (en)	2007-05-21	Use of Biochanine-Enriched Extract for the Treatment of Estrogen-Associated Disorders
NO20041386L (en)	2004-05-11	Combinations for the treatment of immuno-inflammatory disorders
NO20032636D0 (en)	2003-06-11	3-indoline derivatives useful in the treatment of psychiatric and neurological disorders
MXPA03007690A (en)	2003-12-04	Absorbent garment and method of providing the same.
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
NO20030800D0 (en)	2003-02-20	Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, process and preparation containing the same
MXPA01001535A (en)	2003-08-20	Uv-irradiation device for the treatment of wastewater.
ZA200108856B (en)	2002-12-24	Treatment of neurotic disorders.
DK1399424T3 (en)	2008-09-08	Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz [b, f] azepine-5-carboxamide and 10,11-dihydro-10-oxo-5H-dibenz [b, f] azepine-5 carboxamide
ID27214A (en)	2001-03-08	TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
ZA200205098B (en)	2004-03-31	Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
MXPA03004190A (en)	2003-09-22	Treatment of anxiety disorders.
NO20023803L (en)	2002-10-09	Use of mirtazapine for the treatment of sleep disorders
NO20030717L (en)	2003-02-14	Compounds for the treatment of addiction disorders
NO20012612D0 (en)	2001-05-28	Isonipecotamides for the treatment of integrin-mediated disorders
ID30458A (en)	2001-12-06	OSANETAN IN TREATMENT OF SOUL DISORDERS
EE200200670A (en)	2004-08-16	S-methyldihydroziprasidone for the treatment of psychiatric and ocular disorders